AF
DRUG

Allworth Financial’s Bright Minds Biosciences DRUG Stock Holding History

Allworth Financial’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37K Buy
48
+45
+1,500% +$3.53K ﹤0.01% 4307
2026
Q1 		$219 Buy
+3
New +$241 ﹤0.01% 4910

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Allworth Financial's DRUG Position: Q2 2026 in Review

Allworth Financial increased its Bright Minds Biosciences (DRUG) stake by 1,500% in Q2 2026, buying an estimated $3.53K and bringing the position to 48 shares worth $3.37K. The position accounts for ﹤0.01% of the portfolio, ranked #4307.

Allworth Financial first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Allworth Financial held 48 shares of Bright Minds Biosciences worth $3.37K as of Q2 2026.
  • Allworth Financial bought 45 Bright Minds Biosciences shares in Q2 2026, an estimated $3.53K.
  • Bright Minds Biosciences made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4307 holding.
  • Allworth Financial first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.